Search

everythinglearnresearchcommunity

for

Search:↓

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. L'Oreal's study on Stemoxydine 5% claims a 4% increase in hair density after 3 months, but some users question potential bias.

New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.

The conversation humorously speculates on whether an elderly man's good hairline is due to finasteride, dutasteride, or genetics. It also discusses the role of DHT and genetics in hair loss.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A user is considering microneedling to enhance absorption of a prescribed topical hair loss treatment containing Minoxidil, Dutasteride, and Latanoprost, while already taking oral Minoxidil and Dutasteride. They seek advice on the effectiveness and safety of combining these treatments, especially due to the cost and their desire to maximize results.

A user applied pyrilutamide for 6 months without hair regrowth and is considering stopping due to cost and lack of results. Another user suggests switching to finasteride, which is cheaper and has shown regrowth for them.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

The conversation discusses past and current hair loss treatments, with the user reflecting on expensive peptide treatments like topical Dutasteride, Latanoprost, and others, which were ultimately deemed less effective than oral Dutasteride and Minoxidil. The user now prefers the latter due to their cost-effectiveness and efficacy.

The conversation discusses using Dutasteride, oral Minoxidil, and other medications for hair loss, with the user expressing satisfaction despite potential side effects. The user prefers these treatments to maintain a youthful hairline, despite others suggesting alternative methods.

There is no consensus on how long to wait after dermarolling before applying Minoxidil, with some applying immediately and others waiting up to 24 hours. Users report varying experiences with side effects, and some also use finasteride or dutasteride in their hair loss treatment routines.

The user is considering switching to oral dutasteride, topical minoxidil, retinoic acid, and clobetasol for hair loss treatment, after limited regrowth with finasteride and other topicals. They are seeking a source for clobetasol, as they believe it may help with their condition.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

A new therapy aimed at destroying DHT receptors in the scalp is still in early trials and may take at least 5 years to become available. A sugar-like solution similar to Minoxidil is also in early testing stages and not yet commercialized.

A user experienced increased shedding after adding KX-826 to their long-term finasteride and minoxidil regimen. Another user reported mild side effects from KX-826, such as stomach and testicle pain.

The conversation discusses concerns about RU58841 degrading when exposed to light and transferring pyri to a dark glass bottle to prevent this. The user keeps the pyri out for only two minutes before storing it in a dark place.

Kintor Pharmaceutical's new hair loss treatment, KX-826, is entering the market. Users are eager to see its effectiveness before celebrating.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

A user with stage 1 hair loss is inquiring about the release date of GT20029, hoping to use it instead of Minoxidil and finasteride, as they believe it has better results. They want to know if it will be available in the next couple of years.

The conversation discusses using ketoconazole, an anti-androgen, for hair loss and whether mesotherapy with dermarolling could enhance its absorption into the scalp. The user questions if the typical 2% ketoconazole shampoo dose would be effective when used after dermarolling to target androgen receptors in the scalp.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

The user is excited about an upcoming update for GT20029, expected in March. They express frustration with the negativity on Reddit.

The conversation is about someone who has tried various dosages of finasteride for hair loss without success and is considering switching to dutasteride, which reduces more DHT. They are asking if others have had issues with finasteride but found dutasteride to be more effective without problems.

The conversation is about skepticism regarding new hair loss treatments until they are FDA approved. People have been joking about treatments being 5-7 years away for decades.

A natural compound called C3A from Aronia Chokeberry can help prevent hair loss by counteracting the effects of DHT. The user has been taking 50 grams of dried organic Aronia Chokeberry daily for 30 days and will update with photos in 60 days.

A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.

A user shared their 14-month progress using Pyrilutamide and Minoxidil for hair loss, noting improvement and no side effects with these treatments, unlike their negative experiences with Finasteride and RU58841. They emphasized the importance of consistent application for seeing results.